Atkinson joins Perrigo from Haleon plc, where
he previously served as Interim General Counsel
DUBLIN, Sept. 4,
2024 /PRNewswire/ -- Perrigo Company plc (NYSE:
PRGO), a leading global provider of Consumer Self-Care
Products, today announced the appointment of Charles Atkinson as Executive Vice President,
General Counsel and Secretary. He is a skilled lawyer with nearly
25 years of experience, mostly within the regulated consumer
self-care industry.
President and CEO Patrick
Lockwood-Taylor commented, "I am very excited to welcome
Charles to the Perrigo leadership team. His strategic insights,
deep understanding of global regulatory landscapes and intellectual
property background will be instrumental as we continue to
consumerize our business. I am confident that Charles will play a
vital role in advancing our One
Perrigo vision as we continue to provide trusted self-care
products to consumers around the world."
Mr. Atkinson joins Perrigo after a successful career at Haleon
plc and its prior parent, GSK plc, most recently serving as Interim
General Counsel for Haleon. During his 20-plus year combined tenure
at Haleon/GSK, Mr. Atkinson successfully advised across numerous
transactions and integrations, including the creation of Haleon and
subsequent separation from its parent shareholders GSK and Pfizer.
He has also served as global head of corporate legal and was lead
counsel for various parts of the self-care business, including
supply chain, R&D and innovation, business development, and
intellectual property. This included managing the lifecycle of
regulated healthcare products, advising GSK's largest self-care
business and providing counsel for product development, including
leading the switch for Flonase® to over-the-counter
status. He obtained his law degree from University College
London.
"I am thrilled to join Perrigo at such an exciting time," said
Atkinson. "Together with the talented team, I am confident that we
will further elevate the Company's position as a leader in the
consumer self-care industry. I look forward to working closely with
the entire Perrigo team to deliver value to our stakeholders."
Todd Kingma, who came out of
retirement to serve as Interim Executive Vice President, General
Counsel & Secretary, will work with Mr. Atkinson through a
transitionary period. Mr. Kingma's intimate knowledge of Perrigo
and its global team will allow for a highly seamless
transition.
Lockwood-Taylor commented, "We greatly appreciate Todd for his
willingness to step in and provide leadership continuity as well as
steady guidance on all legal matters. We wish him all the best as
he resumes his retirement."
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of
Consumer Self-Care Products and over-the-counter (OTC)
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Visit Perrigo online at
www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: supply chain impacts on the Company's
business, including those caused or exacerbated by armed conflict,
trade and other economic sanctions and/or disease; general
economic, credit, and market conditions; the impact of the war
in Ukraine and any escalation thereof, including the
effects of economic and political sanctions imposed by the
United States, United Kingdom, European Union, and other
countries related thereto; the outbreak or escalation of conflict
in other regions where we do business; current and future
impairment charges, including those related to the sale of the Héra
SAS ("HRA Pharma") Rare Diseases Business, if we determine that the
carrying amount of specific assets may not be recoverable from the
expected future cash flows of such assets; customer acceptance of
new products; competition from other industry participants, some of
whom have greater marketing resources or larger market shares in
certain product categories than the Company does; pricing pressures
from customers and consumers; resolution of uncertain tax positions
and any litigation relating thereto, ongoing or future government
investigations and regulatory initiatives; uncertainty regarding
the Company's ability to obtain and maintain its regulatory
approvals; potential costs and reputational impact of product
recalls or sales halts; potential adverse changes to U.S. and
foreign tax, healthcare and other government policy; the effect of
epidemic or pandemic disease; the timing, amount and cost of any
share repurchases (or the absence thereof) and/or any refinancing
of outstanding debt at or prior to maturity; fluctuations in
currency exchange rates and interest rates; the Company's ability
to achieve benefits expected from its sale of the HRA Rare
Diseases Business, including potential earnout payments, and the
risk that potential costs or liabilities incurred or retained in
connection with that transaction may exceed the Company's estimates
or adversely affect the Company's business or operations; and the
risk that potential costs or liabilities incurred or retained in
connection with the sale of the Company's RX business
transaction may exceed the Company's estimates or adversely affect
the Company's business or operations; the Company's ability to
achieve the benefits expected from the acquisitions of HRA Pharma
and Nestlé's Gateway infant formula plant along with the U.S. and
Canadian rights to the GoodStart® infant formula brand and other
related formula brands ("Gateway") and/or the risks that the
Company's synergy estimates are inaccurate or that the Company
faces higher than anticipated integration or other costs in
connection with the acquisitions; risks associated with the
integration of HRA Pharma and Gateway, including the risk that
growth rates are adversely affected by any delay in the integration
of sales and distribution networks; the consummation and success of
other announced and unannounced acquisitions or dispositions, and
the Company's ability to realize the desired benefits thereof; and
the Company's ability to execute and achieve the desired benefits
of announced cost-reduction efforts and other strategic initiatives
and investments, including the Company's ability to achieve the
expected benefits from its ongoing restructuring programs described
herein. Adverse results with respect to pending litigation could
have a material adverse impact on the Company's operating results,
cash flows and liquidity, and could ultimately require the use of
corporate assets to pay damages, reducing assets that would
otherwise be available for other corporate purposes. These and
other important factors, including those discussed under "Risk
Factors" in the Company's Form 10-K for the year
ended December 31, 2023, as well as the Company's subsequent
filings with the United States Securities and Exchange Commission,
may cause actual results, performance or achievements to differ
materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release
are made only as of the date hereof, and unless otherwise required
by applicable securities laws, the Company disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Perrigo Contact
Bradley Joseph, Vice President,
Global Investor Relations & Corporate
Communications, (269) 686-3373 /
bradley.joseph@perrigo.com
Nicholas Gallagher, Senior
Manager, Global Investor Relations & Corporate
Communications, (269) 686-3238 /
nicholas.gallagher@perrigo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-appoints-industry-veteran-charles-atkinson-as-executive-vice-president-general-counsel-and-secretary-302237956.html
SOURCE Perrigo Company plc